UCSF Search Toolbar
UCSF Radiation Oncology
Search

Prostate Cancer

Study Title

Pre-Operative Gleason Score and PSA and Clinical Stage in Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer

Prinicipal Investigators

Study Number

N/A

Status of Trial

Open

Why is this study being done?

Mack Roach III, M.D, from the Department of Radiation Oncology, is conducting a review of your chart to determine the effectiveness of your radiation treatment and whether he can identify factors that may affect outcomes.

You are being asked to participate in this study because you were treated with radiation therapy for prostate cancer at the University of California at San Francisco, San Francisco General Hospital and San Francisco Veterans Administration Medical Center.

 

Contact

Romobia Hutchinson, BS
Email: HutchinsonR@cc.ucsf.edu


Study Title

Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer.

Prinicipal Investigators

Study Number

RTOG 1115

Status of Trial

Open

Why is this study being done?

PURPOSE: This randomized phase III trial is studying the use of hormone therapy, including TAK-700, together with radiation therapy in treating patients with prostate cancer.

Androgens can cause the growth of prostate cancer cells. Drugs, such as steroid 17alpha-monooxygenase TAK-700, when used with other hormone therapy, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x rays to kill tumor cells. This may be an effective treatment for prostate cancer when combined with hormone therapy. Studying quality-of-life in patients having cancer treatment may help identify the intermediate- and long-term effects of treatment on patients with prostate cancer.
Eligible patients:

Histologically confirmed diagnosis of adenocarcinoma of the prostate within 180 days prior to registration at high risk for recurrence as determined by one of the following combinations (risk group):

Gleason Score (GS) ≥ 9, PSA ≤ 150 ng/mL, any T stage
GS ≥ 8, PSA < 20 ng/mL, T stage ≥ T2
GS ≥ 8, PSA ≥ 20-150 ng/mL, any T stage
GS ≥ 7, PSA ≥ 20-150 ng/mL, any T stage


Patients are randomized to one of the two following treatments. The patient nor their doctor can choose which treatment.

Standard treatment Arm I
Patients receive standard androgen suppression (AS) with a luteinizing hormone-releasing hormone (LHRH) agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 24 months from initiation and oral (PO) antiandrogen (such as flutamide or bicalutamide) beginning 2 months prior and for the duration of radiation therapy (RT).

Experimental: Arm II
Patients receive the same standard AS with a LHRH agonist and oral antiandrogen as in arm 1. Patients also receive steroid 17alpha-monooxygenase TAK-700 (TAK-700) PO twice daily (BID) for 2 years.

Contact

Romobia Hutchinson, BS
Email: HutchinsonR@cc.ucsf.edu


Study Title

A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer.

Prinicipal Investigators

Study Number

RTOG 0924

Status of Trial

Open

Why is this study being done?

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.

PURPOSE: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.

If you agree to participate in this study, you will receive one of these 2 treatments.

 

Contact

Romobia Hutchinson, BS
Email: HutchinsonR@cc.ucsf.edu